

Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



F.No.:908

August 12, 2024

Corporate Relations
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

Dear Sir,

Sub: Outcome of Board Meeting and Unaudited Financial Results - Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Ref: Scrip Code 506414

We write to inform you that the Board of Directors of the Company at its meeting held on August 12, 2024 has, *inter alia*, approved unaudited Financial Results for the quarter ended June 30, 2024 (Standalone and Consolidated) as enclosed.

We are enclosing herewith the Limited Review Reports on the aforesaid results (Standalone and Consolidated) dated August 12, 2024 issued by the Company's Statutory Auditors, S R B C & Co. LLP, Chartered Accountants.

Kindly take the above on record.

The Board meeting commenced at 12:00 noon (IST) and concluded at 1.45 p.m.

Thanking you,

Yours faithfully,

For **Fermenta Biotech Limited**

Varadvinayak Khambete
Company Secretary & Head - Legal
Membership No. A33861

Encl: As above

Factory : Village Takoli, P.O. Nagwain,
Dist. Mandi - 175 121, Himachal Pradesh, India.
Tel. : +91-1905-287246 / 48 / 49
Fax: +91-1905-287250
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,
Taluka - Vagara, Dist: Bharuch - 392 130,
Gujarat, India.
Tel. : +91-2641-291440 / 444
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**Review Report to
The Board of Directors
Fermenta Biotech Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Fermenta Biotech Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
Chartered Accountants
ICAI Firm registration number: 324982E/E300003

Poonam Tadarwal

per Poonam Tadarwal
Partner
Membership No.: 136454
UDIN: 24136454 BKFD04471
Place: Mumbai
Date: August 12, 2024





Fermenta Biotech Limited
CIN:L99999MH1951PLC008485
Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
Tel:+91-22-67980888, Fax:+91-22-67980999 Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

(₹ in Lakhs)

Sr.No.	Particulars	Standalone			
		Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
		June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024
			(Note 7)		
1	Income				
	a) Revenue from operations (refer note 4)	7,269.77	8,965.50	7,677.54	30,709.04
	b) Other income	262.75	149.77	205.41	815.42
2	Total Income (a+b)	7,532.52	9,115.27	7,882.95	31,524.46
3	Expenses				
	a) Cost of materials consumed	2,700.91	3,209.97	2,257.62	8,378.52
	b) Purchases of stock-in-trade	143.08	87.50	103.12	778.38
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(218.82)	(328.82)	148.64	1,386.28
	d) Employee benefits expense	1,454.70	1,368.07	1,355.19	5,393.25
	e) Finance costs	342.33	341.49	475.69	1,705.21
	f) Depreciation and amortisation expense	586.49	620.02	569.31	2,369.55
	g) Other expenses	3,008.86	3,736.41	2,494.47	11,074.03
	Total expenses (a to g)	8,017.55	9,034.64	7,404.04	31,085.22
4	Profit before Exceptional Items and tax (2-3)	(485.03)	80.63	478.91	439.24
5	Exceptional Items (refer note 5)	-	-	-	(900.00)
6	Profit/(Loss) after Exceptional Items and before tax (4-5)	(485.03)	80.63	478.91	(460.76)
7	Tax expense/(income)				
	a) Current tax	-	168.02	-	168.02
	b) Adjustment of tax related to earlier years (refer note 6)	-	637.28	-	1,245.55
	c) Deferred tax charge	-	-	-	-
	Total tax expense/(income) (a+b+c)	-	805.30	-	1,413.57
8	Profit/(Loss) for the period/year after tax (6-7)	(485.03)	(724.67)	478.91	(1,874.33)
9	Other Comprehensive Income				
(A)	i) Items that will not be reclassified to Profit or Loss	-	12.28	-	12.28
	ii) Income tax thereon	-	-	-	-
(B)	Items that will be reclassified to Profit or Loss (net of tax)	0.96	5.69	1.85	6.75
	Total other comprehensive Income/(Loss)	0.96	17.97	1.85	19.03
10	Total Comprehensive Income/(Loss) for the period/year (8+9)	(484.07)	(706.70)	480.76	(1,855.30)
11	Paid-up equity share capital (Face value ₹ 5/- per share)	1,444.70	1,443.71	1,442.87	1,443.71
12	- 28,894,061 number of equity shares				
12	Other equity (excluding revaluation reserve)				29,978.90
13	Earnings per equity share of ₹ 5 each (not annualised)				
	Earnings per equity share of ₹ 5 each before exceptional items				
a)	₹ Basic	(1.68)	(2.51)	1.66	(3.37)
b)	₹ Diluted	(1.68)	(2.51)	1.66	(3.37)
	Earnings per equity share of ₹ 5 each after exceptional items				
a)	₹ Basic	(1.68)	(2.51)	1.66	(6.49)
b)	₹ Diluted	(1.68)	(2.51)	1.66	(6.49)



SIGNED FOR IDENTIFICATION
BY 
S R B C & CO LLP
MUMBAI

See accompanying notes to the Standalone financial results

NOTES:		Standalone				(₹ in Lakhs)
1 Segment Information						
Particulars	Quarter ended			Unaudited	Year Ended	
	Unaudited June 30, 2024	Audited March 31, 2024 (Note 7)	Unaudited June 30, 2023	Audited March 31, 2024	Audited March 31 2024	
Segment revenue	7,007.24	8,211.99	5,056.09	22,698.29		
- Bulk drugs/chemicals	246.98	412.82	2,603.32	7,374.15		
- Property (Refer Note 4)	278.30	490.46	223.54	1,452.02		
- Unallocated	7,532.52	9,115.27	7,882.95	31,524.46		
Total Income						
Segment results	(115.25)	283.24	(1,435.01)	(4,396.46)		
- Bulk drugs/chemicals	109.38	194.56	2,397.11	6,523.94		
- Property	(136.83)	(55.68)	(7.50)	16.97		
- Unallocated (Net)	(142.70)	422.12	954.60	2,144.45		
Total Profit before tax and finance cost	(342.33)	(341.49)	(475.69)	(1,705.21)		
- Finance costs	(485.03)	80.63	478.91	439.24		
Total Profit before Exceptional item and tax	-	-	-	(900.00)		
- Exceptional item (refer note 5)	(485.03)	80.63	478.91	(460.76)		
Total Profit/(loss) before tax						
Segment Assets	45,700.65	45,876.77	49,253.14	45,876.77		
- Bulk Drugs/chemicals	1,238.49	1,481.83	2,036.32	1,481.83		
- Property	7,276.25	9,099.24	13,109.65	9,099.24		
- Unallocated	54,215.39	56,457.84	64,399.11	56,457.84		
Total Segment Assets	7,312.34	7,288.68	5,909.84	7,288.68		
Segment Liabilities	4,150.77	4,208.26	4,599.93	4,208.26		
- Bulk Drugs/chemicals	11,797.07	13,538.29	19,798.12	13,538.29		
- Property	23,260.18	25,035.23	30,307.89	25,035.23		
- Unallocated						
Total Segment Liabilities						



SIGNED FOR IDENTIFICATION
BY
S R B C & CO LLP
MUMBAI

- 2 The above Unaudited standalone financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on on 12th August, 2024. The results of the Company are available for investors at www.fermentabiotech.com and www.bseindia.com.
- 3 These Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year ended March 31, 2024, the Company had sold part of its Investment in Property consisting of floors sales in Thane One IT/ITES building and freshhold land located at Village Takawe and accordingly income on sale of such property for the year ended March 31, 2024 ₹ 6387.82 lakhs (for the quarter ended June 30, 2024 is ₹ Nil, quarter ended March 31, 2024 is ₹ 192.69 lakhs and for the quarter ended June 30, 2023 ₹ 2312.37 lakhs) was recognised as income under the head 'Revenue from operation' pertaining to property segment.
- 5 During the previous year ended March 31, 2024, considering the prolonged subdued global demands, the Company had revisited its projected future cash flows from its subsidiary Fermenta USA LLC and had determined the value in use of its investments in the said subsidiary. Accordingly, a provision for impairment of ₹ 900 lakhs was recorded as an exceptional item.
- 6 During the previous year ended March 31, 2024, the Company had received intimation / final assessment order for the financial years 2016-17 to 2021-22 basis which an additional provision of tax was required on account of certain disallowances. Accordingly total MAT credit recognised of ₹ 1129.83 lakhs and Tax receivable recognised of ₹ 115.72 lakhs was written off during the year relating to such earlier years. (for the quarter ended June 30, 2024 is ₹ Nil, quarter ended March 31, 2024 is ₹ 637.28 lakhs and for quarter ended June 30, 2023 is ₹ Nil)
- 7 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and the unaudited published year to date figures upto the nine months ended December 31, 2023 financial year which were subjected to a limited review by the statutory auditors.

Place: Thane

Date: 12th August, 2024



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Fermenta Biotech Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Fermenta Biotech Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its associate for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Parent Company:

- i. Fermenta Biotech Limited

Subsidiaries:

- i. Fermenta Biotech (UK) Limited
- ii. Fermenta Biotech GmbH
- iii. Fermenta Biotech USA LLC
- iv. Fermenta USA LLC

Associate:

- i. Health and Wellness India Private Limited



S R B C & CO LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes the unaudited interim financial results and other financial information, in respect of:
 - 3 subsidiaries, whose unaudited interim financial results include total revenues of Rs 908.82 lakhs, total net loss after tax of Rs. 138.05 lakhs, total comprehensive loss of Rs. 138.05 lakhs for the quarter ended June 30, 2024 which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

7. The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of:
 - 1 subsidiary, whose interim financial results and other financial information reflect total revenues of Rs. Nil, total net profit after tax of Rs. 0.07 lakhs, total comprehensive income of Rs. 0.07 lakhs, for the quarter ended June 30, 2024.
 - 1 associate, whose interim financial results includes the Group's share of net loss of Rs. Nil and Group's share of total comprehensive loss of Rs. Nil, for the quarter ended June 30, 2024

The unaudited interim financial results and other unaudited financial information of the above subsidiary and associate have not been reviewed by their auditors and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of the subsidiary and associate, is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 and 7 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

For S R B C & CO LLP

Chartered Accountants

ICAI Firm registration number: 324982E/E300003

Poonam Tadarwal

per Poonam Tadarwal

Partner

Membership No.: 136454

UDIN: 24136454BKFOFY7946

Place: Mumbai

Date: August 12, 2024





Fermenta Biotech Limited
 CIN: L99999MH1951PLC008485
 Regd. Office: A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwada, Thane (West) 400 610, Maharashtra, India.
 Tel: +91-22-67980888, Fax: +91-22-67980999, Email: info@fermentabiotech.com, Website: www.fermentabiotech.com

(₹ in Lakhs)

STATEMENT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024

Sr No.	Particulars	Consolidated			
		Quarter Ended		Year Ended	
		Unaudited	Audited	Unaudited	Audited
	June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024	
1	Income				
	a) Revenue from operations (refer note 4)	7,813.17	9,733.85	8,244.82	33,566.19
	b) Other income	281.78	538.15	200.68	1,180.83
2	Total income (a+b)	8,094.95	10,272.00	8,445.50	34,747.02
3	Expenses				
	a) Cost of materials consumed	2,719.22	2,969.75	2,093.93	7,700.48
	b) Purchases of stock-in-trade	417.61	733.62	474.81	2,701.99
	c) Change in inventories of finished goods, stock-in-trade and work-in-progress	(217.54)	78.75	389.79	2,611.46
	d) Employee benefits expense	1,577.57	1,486.26	1,469.15	5,854.79
	e) Finance costs	343.22	338.92	478.41	1,704.60
	f) Depreciation and amortisation expense	612.28	645.69	594.73	2,471.93
	g) Other expenses	3,235.89	3,928.12	2,723.54	11,946.43
	Total expenses (a to g)	8,688.25	10,181.11	8,224.36	34,991.68
4	Profit/(Loss) before Exceptional Items and tax (2-3)	(593.30)	90.89	221.14	(244.66)
5	Exceptional Items (refer note 5)	-	-	-	(742.64)
6	Profit/(Loss) after Exceptional Items and before tax (4-5)	(593.30)	90.89	221.14	(987.30)
7	Tax expense/(income)	-	-	-	-
	a) Current tax	-	168.02	-	168.02
	b) Adjustment of Tax related to earlier years (refer note 6)	-	637.28	-	1,245.55
	c) Deferred tax charge/(credit)	-	-	-	-
	Total tax expense/(income) (a+b+c)	-	805.30	-	1,413.57
8	Profit/(Loss) for the period after tax but before share of profit/(loss) of an associate(6-7)	(593.30)	(714.41)	221.14	(2,400.87)
9	Share of profit / (loss) of an associate	-	-	-	-
10	Net Profit/(Loss) after tax (8-9)	(593.30)	(714.41)	221.14	(2,400.87)
11	Attributable to:				
	- Owners of the parent	(581.90)	(694.07)	183.26	(2,305.98)
	- Non-controlling interests	(11.40)	(20.34)	37.88	(94.89)
12	Other Comprehensive Income/(Loss)				
	(A) Items that will not be reclassified to Profit or Loss				
	i) Remeasurements of defined benefit plan	-	-	-	-
	Income tax thereon	-	-	-	-
	(B) Items that will be reclassified to Profit or Loss (net of tax)				
	i) Exchange differences in translating the financials statements of foreign exchange	30.46	81.29	(17.72)	(34.45)
	ii) Net fair value change in investment in equity instruments through other comprehensive income	0.96	5.69	1.85	6.75
	Total other comprehensive Income/(Loss) (A+B)	31.42	99.26	(15.87)	(15.42)
13	Total Comprehensive Income/(Loss) for the period/year (10+12)	(561.88)	(615.15)	205.27	(2,416.29)
	Attributable to:				
	- Owners of the parent	(550.48)	(594.81)	243.15	(2,321.40)
	- Non-controlling interests	(11.40)	(20.34)	(37.88)	(94.89)
14	Paid-up equity share capital (Face value ₹ 5/- per share)	1,444.70	1,443.71	1,442.87	1,443.71
	- 28,894,061 number of equity shares	-	-	-	-
15	Other equity (excluding revaluation reserve)				
	Earnings per equity share of ₹ 5 each (not annualised)				
	a) ₹ Basic	(2.01)	(2.41)	0.64	(5.42)
	b) ₹ Diluted	(2.01)	(2.41)	0.64	(5.42)
16	Earnings per equity share of ₹ 5 each after exceptional items				
	a) ₹ Basic	(2.01)	(2.41)	0.64	(7.99)
	b) ₹ Diluted	(2.01)	(2.41)	0.64	(7.99)
	See accompanying notes to the Consolidated financial results				



SIGNED FOR IDENTIFICATION
 BY
 ff
S R B C & CO LLP
MUMBAI

NOTES:

1 Segment Information

Particulars	Consolidated					Year Ended Audited
	Quarter ended		Unaudited		Year Ended Audited	
	Unaudited	Audited	Unaudited	Unaudited		
	June 30, 2024	March 31, 2024	June 30, 2023	March 31, 2024		
			(Note 7)			
Segment revenue	7,569.67	9,370.26	5,618.66	25,920.84		
- Bulk drugs/chemicals	246.98	412.82	2,603.32	7,374.15		
- Property (refer note 4)	278.30	488.92	223.52	1,452.03		
- Unallocated	8,094.95	10,272.00	8,445.50	34,747.02		
Total Income						
Segment results	(222.66)	290.48	(1,690.00)	(5,081.40)		
- Bulk drugs/chemicals	109.38	194.56	2,397.11	6,523.94		
- Property	(136.80)	(55.23)	(7.56)	17.40		
- Unallocated (Net)	(250.08)	429.81	699.55	1,459.94		
Total Profit/(Loss) before tax and before finance cost	(343.22)	(338.92)	(478.41)	(1,704.60)		
Less : Finance costs	(593.30)	90.89	221.14	(244.66)		
Total Profit/(Loss) before Exceptional item and tax	-	-	-	(742.64)		
Exceptional item (Refer Note 5)	(593.30)	90.89	221.14	(987.30)		
Total Profit/(Loss) before tax						
Segment Assets	43,964.36	44,201.98	47,995.37	44,201.98		
- Bulk Drugs/chemicals	1,238.49	1,481.83	2,036.32	1,481.83		
- Property	7,284.56	9,099.27	13,109.65	9,099.27		
- Unallocated	52,487.41	54,783.08	63,141.34	54,783.08		
Total Segment Assets	8,571.53	8,520.60	7,272.74	8,520.60		
Segment Liabilities	4,150.77	4,208.26	4,599.93	4,208.26		
- Bulk Drugs/chemicals	11,805.35	13,537.91	19,798.15	13,537.91		
- Property	24,527.65	26,266.77	31,670.82	26,266.77		
- Unallocated						
Total Segment Liabilities						



SIGNED FOR IDENTIFICATION
BY
R
S R B C & CO LLP
MUMBAI

- 2 The above Unaudited consolidated financial results have been reviewed and recommended to the Board of Directors by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 12th August 2024. The results of the Group are available for investors at www.fermentabiotech.com and www.bseindia.com.
- 3 These Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in the Companies (Indian Accounting Standards) Rules 2015 (as amended) ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
- 4 During the previous year ended March 31, 2024, the parent Company had sold part of its Investment in Property consisting of floors sales in Thane One IT/ITES building and freehold land located at Village Takawe and accordingly income on sale of such property for the year ended March 31, 2024 ₹ 6387.82 lakhs (for the quarter ended June 30, 2024 is ₹ Nil, quarter ended March 31, 2024 ₹ 192.69 lakhs and quarter ended June 30, 2023 ₹ 2312.37 lakhs) was recognised as income under the head 'Revenue from operation' pertaining to property segment.
- 5 During the previous year ended March 31, 2024, considering the prolonged subdued global demand, the Group had revisited its forecast of future cash flows of the business pertaining to Fermenta USA LLC. Accordingly an impairment of ₹ 742.64 lakhs was recorded against Goodwill created at the time of acquisition of such subsidiary, which has been disclosed as an exceptional item
- 6 During the previous year ended March 31, 2024, the parent Company had received intimation / final assessment order for the financial years 2016-17 to 2021-22 basis which an additional provision of tax was required on account of certain disallowances. Accordingly total MAT credit recognised of ₹1129.83 lakhs and Tax receivable recognised of ₹115.72 lakhs was written off during the year relating to such earlier years. (for the quarter ended June 30, 2024 is ₹ Nil, quarter ended March 31, 2024 is ₹ 637.28 lakhs and for quarter ended June 30, 2023 is ₹ Nil)
- 7 The figures for the quarter ended March 31, 2024 are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2024 and the unaudited published year to date figures upto the nine months ended December 31, 2023 financial year which were subjected to a limited review by the statutory auditors.

Place: Thane

Date: 12th August, 2024



Prashant Nagre
Managing Director
DIN-9165447